Disorders of sex development (DSD) are phenotypically heterogeneous, ranging from minor genital malformations (hypospadias, cryptorchidism, hypertrophy of the clitoris) to genital ambiguity. In the aggregate, DSD have an estimated incidence of about 1%. DSD can result in severe consequences for behavioral health, fertility, cancer risk and quality of life. For families, the birth of a child with a DSD, and the accompanying uncertainty about future psychological and sexual development, is believed to be extraordinarily stressful. Recently, the debate over clinical management of DSD, in particular gender assignment and genital surgery, has intensified;yet the scientific data on patient outcomes have remained very incomplete. Major obstacles to optimal clinical management of DSD include gaps in understanding of pathophysiology, impeding precise diagnostic categorization, along with the absence of prospective longitudinal studies of health and quality of life outcomes. This proposal delivers a platform for hypothesis-based research on the mechanisms of sex development and evidence-based care for patients and families affected by DSD.
Aim 1 identifies novel genetic mechanisms of sex development and improves understanding of the pathophysiology and molecular diagnosis of DSD by a step-wise approach of specific DNA capture and sequencing, analysis of copy number variants, and identification of novel candidate genes for DSD.
Aim 2 delivers standardized tools for reliable phenotypic descriptions across multiple study sites and investigators, including radiological, biochemical, histological evaluations and descriptions of genital phenotype and post- surgical appearance and function, facilitating interpretation of genetic, gender, and quality of life outcomes Aim 3 identifies short and medium-term outcomes by delivering a comprehensive psychosocial and health-related quality of life assessment battery using psychometrically robust measures suitable for use in routine clinical care, a necessary step leading to evidence-based psychosocial treatment protocols.
Aim 4 builds a sustainable research infrastructure and ensures rapid translation of new evidence into ongoing clinical practice by integrating standardized DSD diagnostic and treatment protocols and fostering the transfer of best practices in healthcare delivery across network sites. This registry provides the analytic platform by which data are collected, analyzed, and shared among researchers and sites, while a collaborative network will supply the foundation for multidisciplinary basic, clinical, and translational research. This unique combination of genetic, phenotypic and psychosocial approaches will transform participating sites into self-sustaining DSD """"""""centers of excellence"""""""" for clinical care along with the added value of a registry serving as a critical resource for hypothesis-driven research.
One of the most defining moments of our lives is when, in the womb, we embark on a male or female path. Disruption of typical male or female development, whether mild or severe, results in Disorders of Sex Development (DSD), which occur quite frequently, in about 1% of the human population. DSD are extremely stressful for parents and, as they grow older, the affected person and are often accompanied by additional medical and psychological problems;yet little is known about the causes of DSD and what healthcare teams should do in the short and long term. We propose to design a way to learn about the genetic causes and the psychological consequences of DSD, and to use these data to provide healthcare teams with procedures to evaluate and improve care for these patients and their families.
|Sandberg, David E; Gardner, Melissa; Callens, Nina et al. (2017) Interdisciplinary care in disorders/differences of sex development (DSD): The psychosocial component of the DSD-Translational research network. Am J Med Genet C Semin Med Genet 175:279-292|
|Rolston, Aimee M; Gardner, Melissa; van Leeuwen, Kathleen et al. (2017) Disorders of sex development (DSD): Clinical service delivery in the United States. Am J Med Genet C Semin Med Genet 175:268-278|
|Byers, Heather M; Mohnach, Lauren H; Fechner, Patricia Y et al. (2017) Unexpected ethical dilemmas in sex assignment in 46,XY DSD due to 5-alpha reductase type 2 deficiency. Am J Med Genet C Semin Med Genet 175:260-267|
|Granados, Andrea; Alaniz, Veronica I; Mohnach, Lauren et al. (2017) MAP3K1-related gonadal dysgenesis: Six new cases and review of the literature. Am J Med Genet C Semin Med Genet 175:253-259|
|Délot, Emmanuèle C; Papp, Jeanette C; DSD-TRN Genetics Workgroup et al. (2017) Genetics of Disorders of Sex Development: The DSD-TRN Experience. Endocrinol Metab Clin North Am 46:519-537|
|Bashamboo, Anu; Donohoue, Patricia A; Vilain, Eric et al. (2016) A recurrent p.Arg92Trp variant in steroidogenic factor-1 (NR5A1) can act as a molecular switch in human sex development. Hum Mol Genet 25:3446-3453|
|Gomez-Lobo, Veronica; Amies Oelschlager, Anne-Marie; North American Society for Pediatric and Adolescent Gynecology (2016) Disorders of Sexual Development in Adult Women. Obstet Gynecol 128:1162-1173|
|Bramble, Matthew S; Goldstein, Ellen H; Lipson, Allen et al. (2016) A novel follicle-stimulating hormone receptor mutation causing primary ovarian failure: a fertility application of whole exome sequencing. Hum Reprod 31:905-14|
|Hipp, Lauren E; Mohnach, Lauren H; Wei, Sainan et al. (2016) Isodicentric Y mosaicism involving a 46, XX cell line: Implications for management. Am J Med Genet A 170A:233-8|
|Ernst, Michelle E; Sandberg, David E; Keegan, Catherine et al. (2016) The Lived Experience of MRKH: Sharing Health Information with Peers. J Pediatr Adolesc Gynecol 29:154-8|
Showing the most recent 10 out of 36 publications